{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:17:02Z","timestamp":1788261422771,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 NS127758"],"award-info":[{"award-number":["U54 NS127758"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R35 ES030443"],"award-info":[{"award-number":["R35 ES030443"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008312","name":"California State University, Fullerton","doi-asserted-by":"publisher","award":["5\\u202FT34 GM149493"],"award-info":[{"award-number":["5\\u202FT34 GM149493"]}],"id":[{"id":"10.13039\/100008312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CHE1726903"],"award-info":[{"award-number":["CHE1726903"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["HHSN-271-2018-00023-C"],"award-info":[{"award-number":["HHSN-271-2018-00023-C"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R16GM149204"],"award-info":[{"award-number":["R16GM149204"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bmc.2025.118112","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:15:12Z","timestamp":1739819712000},"page":"118112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Structure-activity relationship studies and pharmacological evaluation of 4-phenylthiazoles as dual soluble epoxide hydrolase\/fatty acid amide hydrolase inhibitors"],"prefix":"10.1016","volume":"121","author":[{"given":"Cassandra","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Berumen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anesa","family":"Mesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissette","family":"Dubon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Pavana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Gorostiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Morisseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Hammock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan","family":"Pecic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118112_b0005","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1517\/17460440903018857","article-title":"Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders","volume":"4","author":"Ahn","year":"2009","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmc.2025.118112_b0010","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118112_b0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00008877-200509000-00004","article-title":"Endocannabinoids in the regulation of appetite and body weight","volume":"16","author":"Kirkham","year":"2005","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.bmc.2025.118112_b0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.bjp.0707433","article-title":"Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain","volume":"152","author":"Jhaveri","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118112_b0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.neuropharm.2017.06.015","article-title":"The cannabinoid system and pain","volume":"124","author":"Woodhams","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmc.2025.118112_b0030","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nn.2632","article-title":"Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism","volume":"13","author":"Clapper","year":"2010","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bmc.2025.118112_b0035","doi-asserted-by":"crossref","unstructured":"Woodhams, S. G.; Sagar, D. R.; Burston, J. J.; Chapman, V., The Role of the Endocannabinoid System in Pain. In Pain Control, Schaible, H.-G., Ed. Springer Berlin Heidelberg: Berlin, Heidelberg, 2015; pp 119-143.","DOI":"10.1007\/978-3-662-46450-2_7"},{"key":"10.1016\/j.bmc.2025.118112_b0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","article-title":"Modulation of anxiety through blockade of anandamide hydrolysis","volume":"9","author":"Kathuria","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2025.118112_b0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/FBP.0000000000000023","article-title":"Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats","volume":"25","author":"Kwilasz","year":"2014","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.bmc.2025.118112_b0050","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","article-title":"Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids","volume":"285","author":"Node","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118112_b0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0163-7827(03)00049-3","article-title":"Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function","volume":"43","author":"Spector","year":"2004","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.bmc.2025.118112_b0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","article-title":"Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2025.118112_b0065","doi-asserted-by":"crossref","first-page":"C996","DOI":"10.1152\/ajpcell.00402.2006","article-title":"Action of epoxyeicosatrienoic acids on cellular function","volume":"292","author":"Spector","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.bmc.2025.118112_b0070","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.plipres.2013.11.003","article-title":"Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer","volume":"53","author":"Zhang","year":"2014","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.bmc.2025.118112_b0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1476-511X-12-151","article-title":"The role of 14,15-dihydroxyeicosatrienoic acid levels in inflammation and its relationship to lipoproteins","volume":"12","author":"Yang","year":"2013","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.bmc.2025.118112_b0080","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1194\/jlr.M094219","article-title":"Epoxyeicosatrienoic acid (EET)-stimulated angiogenesis is mediated by epoxy hydroxyeicosatrienoic acids (EHETs) formed from COX-2","volume":"60","author":"Rand","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bmc.2025.118112_b0085","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/acs.jmedchem.1c00028","article-title":"Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery","volume":"64","author":"Obeng","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118112_b0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pharmthera.2017.06.006","article-title":"Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases","volume":"180","author":"Wagner","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2025.118112_b0095","doi-asserted-by":"crossref","DOI":"10.1177\/17448069231178176","article-title":"Inflammation in pathogenesis of chronic pain: Foe and friend","volume":"19","author":"Fang","year":"2023","journal-title":"Mol Pain"},{"key":"10.1016\/j.bmc.2025.118112_b0100","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/acs.jmedchem.0c01886","article-title":"Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative","volume":"64","author":"Hammock","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118112_b0105","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.RES.87.11.992","article-title":"Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids","volume":"87","author":"Yu","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.bmc.2025.118112_b0110","doi-asserted-by":"crossref","first-page":"13646","DOI":"10.1073\/pnas.0605908103","article-title":"Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors","volume":"103","author":"Schmelzer","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2025.118112_b0115","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/bcp.12855","article-title":"Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor","volume":"81","author":"Lazaar","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2025.118112_b0120","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.1073\/pnas.0503279102","article-title":"Soluble epoxide hydrolase is a therapeutic target for acute inflammation","volume":"102","author":"Schmelzer","year":"2005","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2025.118112_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2021.106604","article-title":"The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells","volume":"158","author":"Mashayekhi","year":"2022","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.bmc.2025.118112_b0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.phrs.2015.04.001","article-title":"Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive","volume":"97","author":"Sasso","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2025.118112_b0135","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118112_b0140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13020-023-00853-2","article-title":"Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine","volume":"18","author":"Li","year":"2023","journal-title":"Chin Med"},{"key":"10.1016\/j.bmc.2025.118112_b0145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nature11127","article-title":"Chemical genetic discovery of targets and anti-targets for cancer polypharmacology","volume":"486","author":"Dar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118112_b0150","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: Challenges and Opportunities in Drug Discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118112_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104165","article-title":"Development of multitarget inhibitors for the treatment of pain: Design, synthesis, biological evaluation and molecular modeling studies","volume":"103","author":"Wilt","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118112_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116507","article-title":"Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase\/fatty acid amide hydrolase inhibitors","volume":"51","author":"Wilt","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118112_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2022.106702","article-title":"Structure-activity relationship studies of benzothiazole-phenyl analogs as multi-target ligands to alleviate pain without affecting normal behavior","volume":"164","author":"Angelia","year":"2023","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.bmc.2025.118112_b0170","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/0006-2952(94)90520-7","article-title":"Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance","volume":"47","author":"Brian Houston","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2025.118112_b0175","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1126\/science.1076535","article-title":"Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling","volume":"298","author":"Bracey","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118112_b0180","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1073\/pnas.94.6.2238","article-title":"Molecular characterization of human and mouse fatty acid amide hydrolases","volume":"94","author":"Giang","year":"1997","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2025.118112_b0185","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jmb.2010.05.034","article-title":"Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation","volume":"400","author":"Mileni","year":"2010","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmc.2025.118112_b0190","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.bmcl.2012.11.084","article-title":"Synthesis and structure\u2013activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors","volume":"23","author":"Pecic","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118112_b0195","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1002\/chem.200501519","article-title":"Theoretical Study of the Full Reaction Mechanism of Human Soluble Epoxide Hydrolase","volume":"12","author":"Hopmann","year":"2006","journal-title":"Chem \u2013 Eur J"},{"key":"10.1016\/j.bmc.2025.118112_b0200","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/acs.jcim.5b00592","article-title":"Discovery of Potent Soluble Epoxide Hydrolase (sEH) Inhibitors by Pharmacophore-Based Virtual Screening","volume":"56","author":"Waltenberger","year":"2016","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2025.118112_b0205","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1021\/jm201468j","article-title":"Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications","volume":"55","author":"Shen","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118112_b0210","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1021\/jm500694p","article-title":"Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy","volume":"57","author":"Lee","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118112_b0215","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.gene.2013.05.008","article-title":"Soluble epoxide hydrolase: gene structure, expression and deletion","volume":"526","author":"Harris","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.bmc.2025.118112_b0220","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bmcl.2011.10.074","article-title":"Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase","volume":"22","author":"Pecic","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118112_b0225","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0304-3959(77)90130-0","article-title":"The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats","volume":"4","author":"Dubuisson","year":"1977","journal-title":"Pain"},{"key":"10.1016\/j.bmc.2025.118112_b0230","doi-asserted-by":"crossref","first-page":"891","DOI":"10.12688\/f1000research.18338.1","article-title":"A refinement to the formalin test in mice","volume":"8","author":"Lopes","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.bmc.2025.118112_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32262","article-title":"Quinolinyl-based multitarget-directed ligands with soluble epoxide hydrolase and fatty acid amide hydrolase inhibitory activities: Synthetic studies and pharmacological evaluations","volume":"10","author":"Angelia","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bmc.2025.118112_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadva.2024.100119","article-title":"4-Phenyl-thiazole-based dual inhibitors of fatty acid amide hydrolase and soluble epoxide hydrolase do not alleviate orofacial inflammatory pain in female rats","volume":"6","author":"Carr","year":"2024","journal-title":"BBA Adv"},{"key":"10.1016\/j.bmc.2025.118112_b0245","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1021\/acs.jmedchem.9b01220","article-title":"The Blood-Brain Barrier (BBB) Score","volume":"62","author":"Gupta","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118112_b0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ab.2006.10.041","article-title":"Development of highly sensitive fluorescent assays for fatty acid amide hydrolase","volume":"363","author":"Huang","year":"2007","journal-title":"Anal Biochem"},{"key":"10.1016\/j.bmc.2025.118112_b0255","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ab.2005.03.041","article-title":"Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies","volume":"343","author":"Jones","year":"2005","journal-title":"Anal Biochem"},{"key":"10.1016\/j.bmc.2025.118112_b0260","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/cbdd.13670","article-title":"Design, microwave-assisted synthesis, biological evaluation and molecular modeling studies of 4-phenylthiazoles as potent fatty acid amide hydrolase inhibitors","volume":"95","author":"Wilt","year":"2020","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2025.118112_b0265","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.prostaglandins.2018.02.004","article-title":"Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability","volume":"136","author":"Pecic","year":"2018","journal-title":"Prostaglandins Other Lipid Mediat"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625000537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625000537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:29:23Z","timestamp":1777602563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625000537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":53,"alternative-id":["S0968089625000537"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118112","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-activity relationship studies and pharmacological evaluation of 4-phenylthiazoles as dual soluble epoxide hydrolase\/fatty acid amide hydrolase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118112"}}